As per a report by the American Cancer Society, an estimated 22,280 women in the United States are expected be diagnosed with ovarian cancer in 2016, and most of these are high-grade serous ovarian cancers (HGSC), which begin in a fallopian tube. The five-year survival rate for women, with all types of ovarian and fallopian cancer, is 46%. This type of cancer is diagnosed before spreading outside of the tubes in only about 15% of the cases. The survival rate for such cases is almost 90%.
Global Fallopian Tube Cancer - Market Dynamics
The report details several factors driving and restraining the market, some of which are discussed below.
Rise in awareness about the type of cancer and available therapies
Increasing health care expenditure
High cost associated with the surgery and therapy
Adverse side-effects of treatment and toxicity of drugs
The global fallopian tube cancer market has been segmented by type of therapy into surgery (salpingo-oophorectomy and cytoreductive/debulking surgery, among others), chemotherapy and radiation therapy. The drugs that can be used as chemotherapy agents include Taxol (Paclitaxel), Avastin (Bevacizumab), Cisplatin, Evacet (Doxorubicin Hydrochloride Liposome), Doxorubicin Hydrochloride, Gemzar (Gemcitabine Hydrochloride), among multiple others. The market has been geographically segmented into North America, Europe, Asia-Pacific, and Rest of the World.
Major Companies in the Sector Include:
This Report Offers:
Market definition, along with identification of key drivers and restraints for the market.
Market analysis with region-specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.
A comprehensive list of key market players, along with the analysis of their current strategic interests and key financial information.
An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain critical insight into the factors driving and restraining the market, in addition to opportunities, offered.
1.1 Study Deliveratives
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
1.7 Report Description
2. RESEARCH METHODOLOGY
2.2 Analysis Methodology
2.3 Study timeline
2.4 Study Phases
2.4.1 Secondary Research
2.4.2 Discussion Guide
2.4.3 Market Engineering & Econometric Model
2.4.4 Expert Validation
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW AND INDUSTRY TRENDS
5.1 Current Market Scenario
5.2 Market Overview
5.3 Porters Five Force Analysis
5.3.1 Bargaining Power Of Suppliers
5.3.2 Bargaining Power Of Buyers
5.3.3 Degree Of Competition
5.3.4 Threat Of Substitution
5.3.5 Threat Of New Entrants
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 Market Drivers
6.1.1 Rise in Awareness About the Type of Cancer and Available Therapies
6.1.2 Increasing Health Care Expenditure
6.2 Market Restraints
6.2.1 High-Cost Associated with the Surgery and Therapy
6.2.2 Adverse Side Effects of Treatment and Toxicity of Drugs
6.3 Market Opportunities
6.4 Key Challenges
7. Global Fallopian Tube Cancer Market - Segmentation
7.1 By Type of Therapy
220.127.116.11 Cytoreductive/Debulking Surgery
18.104.22.168 Taxol (Paclitaxel)
22.214.171.124 Avastin (Bevacizumab)
126.96.36.199 Evacet (Doxorubicin Hydrochloride Liposome)
188.8.131.52 Doxorubicin Hydrochloride
184.108.40.206 Gemzar (Gemcitabine Hydrochloride)
7.1.3 Radiation Therapy
8. Global Fallopian Tube Cancer Market - Regional Shares and Forecast
8.1 North America
8.1.1 United States
8.2.5 Spain & Portugal
8.2.8 Rest of Europe
8.3.4 Australia & New Zealand
8.3.5 South Korea
8.3.6 Rest of Asia-Pacific
8.4 The Middle East and Africa
8.4.2 South Africa
8.4.3 Rest of the Middle East and Africa
8.5 Latin America
8.5.3 Rest of Latin America
9. Competitive Landscape
9.1 Merger and Acquisition Analysis
9.2 New Product Launches
9.3 Agreements, Collaborations & Partnerships
10. Company Profiles
10.1 Amgen Inc.
10.4 Boehringer Ingelheim GmbH
10.5 Bristol-Myers Squibb
10.7 Eli Lilly and Company
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market